Cyclin A is a proliferative marker with good prognostic value in node-negative breast cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 9, 2009, Pages 2501-2506

  Ahlin, Cecilia ^a,b   Zhou, Wenjing ^a   Holmqvist, Marit ^c   Holmberg, Lars ^a,d   Nilsson, Cecilia ^a   Jirström, Karin ^e   Blomqvist, Carl ^a,f   Amini, Rose Marie ^a   Fjällskog, Marie Louise ^a,g  

^a UPPSALA UNIVERSITY   (Sweden)

^b ÖREBRO UNIVERSITY   (Sweden)

^c Uppsala Orebro Regional Oncologic Center   (Sweden)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e LUND UNIVERSITY   (Sweden)

^f UNIVERSITY OF HELSINKI   (Finland)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; KI 67 ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER MORTALITY; CANCER RISK; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYCLIN A; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 70349318541     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0169     Document Type: Article

References (24)

1. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006;8:R25. (Pubitemid 43827376)
2. Fisher B, Jeong JH, Bryant J, et al. National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004;364:858-868
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717
4. Cinieri S, Orlando L, Fedele P, et al. Adjuvant strategies in breast cancer: new prospectives, questions and reflections at the end of 2007. St Gallen International Expert Consensus Conference. Ann Oncol 2007;18:vi63-5.
5. Harris L, Fritsche H, Mennel R, Norton L, et al. American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-5312
6. Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008;10:R65.
7. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-272 (Pubitemid 43264710)
8. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-1715 (Pubitemid 14035254)
9. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 2005;1723-1739
10. Zindy F, Lamas E, Chenivesse X, et al. Cyclin A is required in S phase in normal epithelial cells. Biochem Biophys Res Commun 1992;182:1144-1154
11. Bukholm IR, Bukholm G, Nesland JM. Overexpression of cyclin A is highly associated with relapse and reduced survival in patients with primary breast carcinomas. Int J Cancer 2001;93:283-287 (Pubitemid 32574286)
12. Michalides R, van Tinteren H, Balkenende A, et al. Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br J Cancer 2002;86:402-408 (Pubitemid 34185125)
13. Kuhling H, Alm P, Olsson H, Fernö M, Baldetorp B, Parwaresch R. Expression of cyclin E, A and B and prognosis in lymph node-negative breast cancer. J Pathol 2003;199:424-431 (Pubitemid 36411218)
14. Baldini E, Camerini A, Sgambato A, et al. Cyclin A and E2F1 overexpression correlate with reduced disease-free survival in node-negative breast cancer patients. Anticancer Res 2006;26:4415-4421 (Pubitemid 46031516)
15. Ahlin C, Aaltonen K, Nevanlinna H, Fjällskog ML, Blomqvist C. Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values? Histopathology 2007;51:491-498
16. Aaltonen K, Ahlin C, Amini RM, et al. Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slides. Br J Cancer 2006;94:1697-1702 (Pubitemid 43924935)
17. Eaker S, Dickman PW, Hellström V, Zack MM, Ahlgren J, Holmberg L. Regional differences in breast cancer survival despite common guidelines. Cancer Epidemiol Biomarkers Prev 2005;14:2914-2918 (Pubitemid 43068824)
18. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-410
19. Volpi A, Bacci F, Paradiso A, et al. Prognostic relevance of histological grade and its components in node-negative breast cancer patients. Mod Pathol 2004;17:1038-1044 (Pubitemid 39128229)
20. Boiesen P, Bendahl P-O, Anagnostaki L, et al. Histologic grading in breast cancer - reproducibility between seven pathologic departments. Acta Oncol 2000;3:41-45 (Pubitemid 30216614)
21. Mengel M, von Wasielewski R, Wiese B, Rüdiger T, Müller-Hermelink HK, Kreipe H. Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki67 labelling index in a large multi-centre trial. J Pathol 2002;198:292-299 (Pubitemid 35277379)
22. Huuhtanen RL, Wiklund TA, Blomqvist CP, et al. A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients. Br J Cancer 1999;81:1017-1021
23. Sjöström J. Predictive factors for response to chemotherapy in advanced breast cancer. Acta Oncol 2002;41:334-345 (Pubitemid 34941116)
24. Rothman KJ. Epidemiology: an introduction. Oxford: Oxford University Press; 2002;73-81.